Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in antiangiogenic therapy.

Keith Dredge1, Angus G Dalgleish, J Blake Marriott

  • 1Division of Oncology, St. George's Hospital Medical School, Jenner Wing, Cranmer Terrace, Tooting SW17 0RE, London, UK. k.dredge@sghms.ac.uk

Expert Opinion on Biological Therapy
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenografts.

Drug delivery and translational research·2026
Same author

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.

Oncogene·2023
Same author

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.

Journal for immunotherapy of cancer·2023
Same author

The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients.

Oncology letters·2022
Same author

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

ACS central science·2022
Same author

Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy <i>in vitro</i> and <i>in vivo</i>.

Oncology reports·2022
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Antiangiogenic therapy, targeting new blood vessel formation, shows promise for diseases like cancer and psoriasis. Further research is needed to overcome limitations and optimize treatment strategies for better patient outcomes.

Area of Science:

  • Oncology
  • Vascular Biology
  • Dermatology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
  • Antiangiogenic therapy emerged as a potential treatment for various diseases, including cancer and psoriasis.
  • Initial clinical trials for antiangiogenic therapy in cancer yielded disappointing results, necessitating reassessment.

Purpose of the Study:

  • To review the role of angiogenesis in diverse pathological conditions.
  • To discuss emerging antiangiogenic agents in preclinical and clinical development.
  • To explore strategies for enhancing the efficacy of antiangiogenic therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on antiangiogenic agents.

Related Experiment Videos

  • Analysis of the angiogenic process, its inducers, and mediators.
  • Discussion of therapeutic strategies, including drug scheduling and combination therapies.

    • Main Results:

    • Angiogenesis is implicated in difficult-to-treat conditions like arteriosclerosis, arthritis, psoriasis, and diabetic retinopathy.
    • New strategies are being developed to improve the efficacy of antiangiogenic therapy in cancer.
    • Emerging antiangiogenic agents are under investigation in preclinical and clinical studies.

    Conclusions:

    • A deeper understanding of angiogenesis can lead to novel treatment regimens for various diseases.
    • While antiangiogenic therapy holds profound potential benefits, its limitations necessitate cautious clinical application.
    • Optimizing drug schedules and combining antiangiogenic agents with other modalities may improve treatment outcomes.